Pharmacology
Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
A study from Rutgers University reports that adults currently using GLP-1 receptor agonist medications—including semaglutide brands Ozempic and Wegovy—showed a substantially weaker association between impulsivity and self-reported violent behavior than former users. The research, published June 17, 2026 in the journal Criminology, was based on a 2025 U.S. survey and does not establish cause and effect.
A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.
AI에 의해 보고됨
A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.
Researchers have discovered why polyamines, compounds promoted for anti-aging benefits, may also promote cancer growth. The study shows that these molecules activate different proteins in healthy versus cancerous cells, leading to contrasting effects. Led by experts at Tokyo University of Science, the findings were published in the Journal of Biological Chemistry.
AI에 의해 보고됨 사실 확인됨
Researchers at Adelaide University report that salcaprozate sodium (SNAC)—an absorption enhancer used in oral semaglutide tablets—was associated with changes in gut bacteria and inflammation markers in an animal study conducted over 21 days. The authors said the findings do not demonstrate harm in humans but argue that longer-term research is needed as oral options for obesity treatment expand.
After 11 years of research, scientists at McMaster University have identified a molecule called butyrolactol A that weakens deadly fungi, making them vulnerable to existing treatments. This discovery targets pathogens like Cryptococcus neoformans, which pose severe risks to immunocompromised individuals. The finding could revive outdated antifungal drugs amid rising resistance.
AI에 의해 보고됨
New research indicates that regular use of ibuprofen, a common painkiller, may reduce the risk of endometrial cancer by up to 25% in certain women. This finding comes from a large-scale study analyzing over 42,000 participants, highlighting the drug's anti-inflammatory properties. However, experts caution against using it for prevention due to potential side effects.
Study links common IBS drugs to higher long-term death risk
2026년 04월 16일 15시 29분Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance
2026년 04월 15일 12시 08분Hitting urate targets with gout-lowering therapy is linked to lower cardiovascular risk in large UK study
2026년 04월 13일 23시 18분Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial
2026년 04월 11일 11시 25분Scientists stabilize carbene in water, confirming vitamin B1 theory
2026년 02월 27일 07시 08분Researchers create efficient iron photocatalyst for drug synthesis
2026년 02월 17일 03시 36분Study links two somatostatin receptors to the brain’s ability to break down amyloid-beta
2026년 02월 11일 10시 54분Cochrane reviews assess GLP-1 drugs for obesity treatment
2026년 02월 09일 19시 49분Ancient Chinese herb offers potential for hair regrowth
2026년 01월 28일 08시 11분Statins block cancer's PD-L1 evasion in immunotherapy